๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Shenzhen
Clinical trial register · China

Clinical Trials in Shenzhen, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Shenzhen Geno-Immune Medical Institute43 Beijing Biotech32 Sun Yat-sen University23 Bristol-Myers Squibb19 Shenzhen University General Hospital11
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Shenzhen

576 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
By invitation
Adaptive Neoadjuvant Therapy for Esophageal Cancer
NCT06990178Esophageal Carcinoma, Neoadjuvant Therapy
Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
Not applicable
43
Shenzhen
2028-03-01
Not yet open
Combination Immunotherapy Targeting Sarcomas
NCT04433221Sarcoma, Osteoid Sarcoma, Ewing Sarcoma
Shenzhen Geno-Immune Medical Institute
Phase 1/2
20
Shenzhen
2027-07-01
Not yet open
Lentiviral Gene Therapy for CGD
NCT03645486Chronic Granulomatous Disease
Shenzhen Geno-Immune Medical Institute
Not applicable
10
Shenzhen
2027-07-01
Not yet open
CAR-T Immunotherapy Targeting CD19- ALL
NCT04016129B-cell Leukemia
Shenzhen Geno-Immune Medical Institute
Phase 1/2
100
Shenzhen
2027-07-01
Not yet open
Universal CAR-T Cells Targeting AML
NCT05995041Acute Myeloid Leukemia
Shenzhen Geno-Immune Medical Institute
Phase 1
30
Shenzhen
2027-06-30
Not yet open
Engineered Dendritic Cell Vaccines for Multiple Myeloma
NCT06435910Multiple Myeloma or Plasmacytoma
Shenzhen Geno-Immune Medical Institute
Phase 1
10
Shenzhen
2027-06-30
Not yet open
Autoimmune Disease Treatment With Mesenchymal Stem Cells (MSCs) and CAR-T Cells
NCT06435897Autoimmune Diseases
Shenzhen Geno-Immune Medical Institute
Phase 1/2
30
Shenzhen
2027-06-30
Not yet open
Gene Therapy for ADA-SCID Using an Improved Lentiviral Vector (Ivlv-ADA)
NCT03645460Adenosine DeAminase Severe Combined ImmunoDeficiency (ADA-SCID)
Shenzhen Geno-Immune Medical Institute
Not applicable
10
Shenzhen
2027-06-30
Not yet open
SCID-X1 Gene Therapy Via Intravenous Lentiviral (Ivlv-X1) Injection
NCT03217617SCID, X-Linked
Shenzhen Geno-Immune Medical Institute
Phase 1/2
10
Shenzhen
2027-06-30
Not yet open
Combination Immunotherapy Targeting Melanoma
NCT06739226Melanoma
Shenzhen Geno-Immune Medical Institute
Phase 1/2
30
Shenzhen
2027-06-30
Not yet open
cfMSC Stem Cell Therapy Targeting COPD
NCT07477600Chronic Obstructive Pulmonary Disease (COPD)
DrugClonal fetal MSCs
Shenzhen Geno-Immune Medical Institute
Phase 1/2
30
Shenzhen
2027-06-30
Not yet open
Universal 4SCAR7U Targeting CD7-positive Malignancies
NCT05995028T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, Acute Myeloid Leukemia, NK Cell Lymphoma
Shenzhen Geno-Immune Medical Institute
Phase 1
30
Shenzhen
2027-06-30
Not yet open
cfMSC Therapy for Diabetes
NCT07495956Type II Diabetes Mellitus
Shenzhen Geno-Immune Medical Institute
Phase 1/2
30
Shenzhen
2027-06-30
Not yet open
Universal CAR-T Cells Targeting Multiple Myeloma
NCT06006741Multiple Myeloma in Remission
Shenzhen Geno-Immune Medical Institute
Phase 1
20
Shenzhen
2027-06-30
Not yet open
H3K27M-specific Immune Effector Cells Targeting DMG/DIPG
NCT07501156Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma
Shenzhen Geno-Immune Medical Institute
Phase 1/2
30
Shenzhen
2027-06-30
Not yet open
IT and IV Lentiviral Gene Therapy for X-ALD
NCT03727555X-linked Adrenoleukodystrophy
Shenzhen Geno-Immune Medical Institute
Not applicable
30
Shenzhen
2027-06-01
Not yet open
Lentiviral Hematopoietic Stem Cell Gene Therapy for MLD
NCT07046338Metachromatic Leukodystrophy (MLD)
Shenzhen Geno-Immune Medical Institute
Not applicable
10
Shenzhen
2027-06-01
Not yet open
CD19/70 Bi-specific CAR-T Cell Therapy
NCT05436496B Cell Malignancies
Shenzhen Geno-Immune Medical Institute
Phase 1/2
30
Shenzhen
2027-06-01
Not yet open
DLL3 CAR-T Therapy Targeting Brain Tumors
NCT07180927Glioblastoma of Cerebellum
Shenzhen Geno-Immune Medical Institute
Phase 1/2
30
Shenzhen
2027-06-01
Not yet open
Multi-4SCAR-T Therapy Targeting Breast Cancer
NCT04430595Breast Cancer
Shenzhen Geno-Immune Medical Institute
Phase 1/2
100
Shenzhen
2027-06-01
Not yet open
Multi-CAR-T Cells Targeting B Cell Lymphomas
NCT04429438B Cell Lymphoma (BCL)
Shenzhen Geno-Immune Medical Institute
Phase 1/2
11
Shenzhen
2027-06-01
Not yet open
Lentiviral FIX Gene Therapy
NCT03961243Hemophilia B
Shenzhen Geno-Immune Medical Institute
Phase 1
10
Shenzhen
2027-06-01
Not yet open
Targeting CD276 (B7-H3) Positive Solid Tumors by 4SCAR-276
NCT04432649Solid Tumor
Shenzhen Geno-Immune Medical Institute
Phase 1/2
100
Shenzhen
2027-06-01
Not yet open
Lentiviral FVIII Gene Therapy
NCT03217032Hemophilia A
Shenzhen Geno-Immune Medical Institute
Phase 1
10
Shenzhen
2027-06-01
Not yet open
Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas
NCT03356782Sarcoma, Osteoid Sarcoma, Ewing Sarcoma
Shenzhen Geno-Immune Medical Institute
Phase 1/2
20
Shenzhen
2027-06-01
Not yet open
CAR-T Cells Targeting Autoimmune Diseases
NCT05459870Autoimmune Diseases
Shenzhen Geno-Immune Medical Institute
Phase 1/2
30
Shenzhen
2027-06-01
Not yet open
CD19/22 Bi-specific CAR-T Cell Therapy
NCT05432882B Cell Malignancies
Shenzhen Geno-Immune Medical Institute
Phase 1/2
60
Shenzhen
2027-06-01
Not yet open
Immunotherapy Treating GI Cancer
NCT03614650Cancer
Shenzhen Geno-Immune Medical Institute
Phase 1/2
100
Shenzhen
2027-06-01
Not yet open
Antigen-specific T Cells Against Lung Cancer
NCT03356808Lung Cancer
Shenzhen Geno-Immune Medical Institute
Phase 1/2
20
Shenzhen
2027-06-01
Not yet open
Direct Lentiviral Injection Gene Therapy for MLD
NCT03725670Metachromatic Leukodystrophy (MLD)
Shenzhen Geno-Immune Medical Institute
Not applicable
10
Shenzhen
2027-05-31
Not yet open
A Clinical Study to Investigate the Safety and Efficacy of Off-the-Shelf iNKT Cell Injection Targeting CD33/CD70 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT07676006Relapsed/Refractory Acute Myeloid Leukemia (AML)
Grit Biotechnology
Phase EARLY_PHASE1
36
Shenzhen
2027-05
Not yet open
Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma
NCT06429150Multiple Myeloma, Plasmacytoma
Shenzhen Geno-Immune Medical Institute
Phase 1/2
20
Shenzhen
2026-12-31
Not yet open
4SCAR19U T Cells Targeting B Cell Malignancies
NCT05995015B Cell Malignancies
Shenzhen Geno-Immune Medical Institute
Phase 1
30
Shenzhen
2026-12-31
Not yet open
GD2/PSMA Bi-specific CAR-T Cell Therapy
NCT05437315Solid Tumor
Shenzhen Geno-Immune Medical Institute
Phase 1/2
60
Shenzhen
2026-12-31
Not yet open
PSMA-specific CAR-T Cell Therapy
NCT04429451PSMA Positive Tumors or Tumor Tissues
Shenzhen Geno-Immune Medical Institute
Phase 1/2
100
Shenzhen
2026-12-31
Not yet open
Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies
NCT04033302T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, Acute Myeloid Leukemia, NK Cell Lymphoma
Shenzhen Geno-Immune Medical Institute
Phase 1/2
30
Shenzhen
2026-12-31
Not yet open
Immune Modulatory DC Vaccine Against Brain Tumor
NCT03914768Diffuse Intrinsic Pontine Glioma or Glioblastoma
Shenzhen Geno-Immune Medical Institute
Phase 1
10
Shenzhen
2026-12-31
Not yet open
Gene Therapy of Beta Thalassemia Using a Self-inactivating Lentiviral Vector
NCT03351829Beta-Thalassemia
Shenzhen Geno-Immune Medical Institute
Not applicable
20
Shenzhen
2026-12-31
Not yet open
Study on GD2 Positive Solid Tumors by 4SCAR-GD2
NCT02992210Solid Tumor
Shenzhen Geno-Immune Medical Institute
Phase 1/2
10
Shenzhen
2026-12-31
Not yet open
Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma
NCT03271632Multiple Myeloma
Shenzhen Geno-Immune Medical Institute
Phase 1/2
20
Shenzhen
2026-12-31
Not yet open
Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
NCT03222674Acute Myeloid Leukemia
Shenzhen Geno-Immune Medical Institute
Phase 1/2
10
Shenzhen
2026-12-31
Not yet open
4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma
NCT04637503Neuroblastoma
Shenzhen Geno-Immune Medical Institute
Phase 1/2
100
Shenzhen
2026-12-31
Not yet open
GD2/CD70 Bi-specific CAR-T Cell Therapy
NCT05438368Cancer Disease
Shenzhen Geno-Immune Medical Institute
Phase 1/2
30
Shenzhen
2026-12-31
Not yet open
Clonal Fetal Mesenchymal Stem Cells (cfMSCs) for the Control of Immune-related Disorders
NCT03123458Immune Related Disorder, Tissue Damage
DrugClonal fetal MSCs
Shenzhen Geno-Immune Medical Institute
Phase 1
100
Shenzhen
2026-12-31
Not yet open
Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia A
NCT06136507Severe Hemophilia A
DrugFRSW107
Hangzhou Gensciences Biopharmaceutical Co., Ltd.
Phase 3
76
Chongqing, Guangzhou, Guizhou, Hangzhou, Hefei, Nanjing, Qingdao, Shenzhen
2026-12-25
Not yet open
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
NCT07441408Pulmonary Fibrosis
DrugAdmilparant
Bristol-Myers Squibb
Phase 3
2,380
Hefei, Beijing, Shenzhen, Guangzhou, Shenzhen Shi, Zhengzhou, Shijiazhuang, Yichang Shi
2026-12-16
Not yet open
EECP for Erectile Dysfunction in Elderly Hypertensive Patients
NCT07831551Hypertension, Erectile Dysfunction
Qilu Hospital of Shandong University
Not applicable
106
Shenzhen, Jinan
2026-10-01
Not yet open
Yeast Protein Supplementation and Muscle Preservation During GLP-1RA-Induced Weight Loss
NCT07817823Overweight and Obesity in Adults Receiving GLP-1RA Treatment
Huazhong University of Science and Technology
Not applicable
200
Shenzhen
2026-09-20
Not yet open
Finerenone for Premature Ovarian Insufficiency (POI)
NCT07815509Premature Ovarian Insufficiency
DrugFinerenone
The University of Hong Kong-Shenzhen Hospital
Phase 2
46
Shenzhen
2026-09-15
Recruiting
A Clinical Trial of TQH3906 Capsules in Adult Patients With Moderate to Severe Plaque Psoriasis
NCT07724366Psoriasis
DrugsTQH3906·Deucravacitinib
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
400
Beijing, Chongqing, Guangzhou, Shenzhen, Nanning, Guiyang, Haikou, Chengde
2026-09-02
Not yet open
A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Systemic Lupus Erythematosus
NCT07760155Systemic Lupus Erythematosus (SLE)
DrugESG206
Shanghai Escugen Biotechnology Co., Ltd
Phase 2
40
Shenzhen, Zhongshan, Guilin, Liupanshui, Handan, Shijiazhuang, Changde, Changsha
2026-09-01
Not yet open
Online Self-healing Program
NCT07374653Mild to Moderate Depressive Symptoms
City University of Hong Kong
Not applicable
200
Shenzhen
2026-09-01
Recruiting
Efficacy and Safety of Telitacicept in the Treatment of Refractory Rheumatoid Arthritis
NCT07796516Difficult-to-treat Rheumatoid Arthritis, Rheumatoid Arthritis
DrugTelitacicept
Peking University People's Hospital
Phase 2
420
Hefei, Beijing, Chongqing, Quanzhou, Guangzhou, Jiangmen, Shenzhen, Nanning
2026-09-01
Not yet open
Spatially Fractionated Radiation Therapy for Locally Advanced Cervical Cancer
NCT07781475Cervical Cancer
The University of Hong Kong-Shenzhen Hospital
Not applicable
126
Shenzhen
2026-09-01
Not yet open
Video-Assisted Thoracoscopic Surgery Combined With Radiofrequency Ablation Versus VATS Alone for Multiple Primary Lung Cancer
NCT07819669Multiple Primary Lung Cancers
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
160
Taiyuan, Beijing, Shenzhen
2026-09
Not yet open
Efficacy and Safety of Roflumilast Foam 0.3% in Trial Participants With Seborrheic Dermatitis
NCT07683806Seborrheic Dermatitis
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 3
309
Bengbu, Wuhu, Fuzhou, Xiamen, Guangzhou, Shenzhen, Haikou, Baoding
2026-08-24
Recruiting
AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
NCT07797335Type 2 Diabetes, Cardiovascular Risk
DrugZenagamtide
Novo Nordisk A/S
Phase 3
1,778
Hefei, Beijing, Chongqing, Shenzhen, Cangzhou, Langfang, Shijiazhuang, Kaifeng
2026-08-24
Recruiting
Study to Assess Adverse Events and How Effective NOA LIFT is Compared to JUVร‰DERM VOLIFT With Lidocaine for the Correction of Nasolabial Folds in Adults
NCT07794878Nasolabial Folds
AbbVie
Phase 3
288
Beijing, Guangzhou, Shenzhen, Nanjing, Xianyang
2026-08-19
Not yet open
Construction and Validation of a Coronary Artery Disease-Specific Large Language Model and Its Evaluation Framework (CorAI)
NCT07766551Coronary Heart Disease (CHD), Artifical Intelligence
China National Center for Cardiovascular Diseases
Observational
640
Hefei, Beijing, Shenzhen
2026-08-17
Not yet open
A Phase I/II Open-label, Single-arm, Multicenter Clinical Study to Evaluate the Safety and Efficacy of FKC289 in Subjects With Relapsed/Refractory Membranous Nephropathy
NCT07765537Primary Membranous Nephropathy
DrugFKC289
Shenzhen Fosun Kairos Biotechnology Co., Ltd.
Phase 1/2
55
Hefei, Beijing, Guangzhou, Shenzhen, Wuhan, Changsha, Nanjing, Chengdu
2026-08
Not yet open
Diagnostic Accuracy and Safety of the Attention-Deficit/Hyperactivity Disorder Auxiliary Evaluation System (AHEF) in Chinese Children Aged 6 to 12
NCT07683156Attention-Deficit, Hyperactivity Disorder
Chongqing Jinsaixing Medical Technology Co., Ltd
Observational
570
Beijing, Chongqing, Guangzhou, Shenzhen, Nanjing, Changchun, Shanghai, Chengdu
2026-07-31
Not yet open
Clinical Study on the Effectiveness of Antibiotics Combined With Bifidobacterium Quadruple Live Tablets in Treating Cirrhosis With Spontaneous Bacterial Peritonitis and Preventing Recurrence
NCT07686861Cirrhosis With Spontaneous Bacterial Peritonitis
Peking University First Hospital
Phase 4
360
Fuyang, Fuzhou, Xiamen, Lanzhou, Guangzhou, Shenzhen, Guigang, Guiyang
2026-07-31
Recruiting
Individualized Primary Clinical Target Volume Based on Margin Expansion for Nasopharyngeal Carcinoma
NCT07661771Non-metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3
568
Dongguan, Foshan, Guangzhou, Shenzhen, Zhongshan, Changsha
2026-07-24
Recruiting
Study on the Safety and Efficacy of Polymyxin E2 Methanesulfonate for Injection in the Treatment of Hospital-Acquired Bacterial Pneumonia/Ventilator-Associated Bacterial Pneumonia Caused by Carbapenem-Resistant Gram-Negative Bacteria
NCT07512596Hospital-acquired Bacterial Pneumonia/Ventilator-associated Bacterial Pneumonia
DrugsColistimethate sodium·Meropenem
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
48
Bengbu, Beijing, Chongqing, Foshan, Guangzhou, Shenzhen, Zhuhai, Shijiazhuang
2026-07-21
Recruiting
A Clinical Trial of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis
NCT07406035Psoriatic Arthritis
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 2
156
Bozhou, Beijing, Chongqing, Dongguan, Guangzhou, Jiangmen, Shenzhen, Nanning
2026-07-16
Not yet open
Development of a Risk Prediction Model for Post-Spinal Anesthesia Hypotension During Cesarean Delivery Using Heart Rate, Blood Pressure, Perfusion Index, ECG Waveforms, and SpOโ‚‚ Waveforms
NCT07689825Cesarean Section
Peking University Shenzhen Hospital
Observational
145
Shenzhen
2026-07-13
Recruiting
Ruxolitinib Cream Combined With Corticosteroids for Progressive Non-Segmental Vitiligo: A Multicenter Real-World Study
NCT07673640Non-Segmental Vitiligo (NSV)
DrugRuxolitinib Phosphate
ShanShan Li
Observational
300
Shenzhen, Huai'an, Suzhou, Xuzhou, Dongying, Shanghai, Changzhou, Jiaozuo
2026-07-02
Not yet open
Safety and Efficacy of Allogeneic Bone Marrow MSCs in Ankylosing Spondylitis
NCT07632599Ankylosing Spondylitis
Eighth Affiliated Hospital, Sun Yat-sen University
Phase 1
40
Shenzhen
2026-07-01
Recruiting
Chemoradiotherapy and SHR-1701 in Patients With Unresectable Gastric Cancer
NCT07689851Gastric Cancer (GC), Gastroesophageal Junction Adenocarcinoma
DrugSHR-1701
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
60
Shenzhen, Taiyuan, Beijing
2026-07-01
Not yet open
Study on the Effects and Mechanisms of Probiotic Supplementation in Ameliorating Uric Acid Metabolism in Asymptomatic Hyperuricemic Individuals
NCT07650214Asymptomatic Hyperuricemia
Sun Yat-sen University
Not applicable
68
Shenzhen
2026-07-01
Not yet open
Analysis of Different Second Line Treatment in Advanced NSCLC Patients Progressing After 1st Line Immune Checkpoint Inhibitor Therapy
NCT07596524Lung Cancer (NSCLC)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
300
Beijing, Shenzhen, Taiyuan
2026-07-01
Recruiting
Neoadjuvant RC48 Plus Gemcitabine in HER2-Expressing MIBC
NCT07693959MIBC
DrugsDisitamab Vedotin·Gemcitabine·Tislelizumab
Zhiquan Hu
Phase 3
170
Hefei, Fuzhou, Xiamen, Guangzhou, Shenzhen, Enshi, Huanggang, Huangshi
2026-07-01
Active, closed
Efficacy and Accuracy of an AI-Driven Sleep Earbud for Chronic Insomnia
NCT07744581Insomnia, Insomnia Chronic, Insomnia Disorders, Sleep Wake Disorders
The Chinese University of Hong Kong, Shenzhen
Not applicable
25
Shenzhen
2026-07-01
Not yet open
Hexaminolevulinate Photodynamic Therapy (HAL-PDT) With Deferred Surgery Versus Surgery for High-grade Squamous Intraepithelial Lesions (HSIL)
NCT07669363Cervical Intraepithelial Neoplasia, Papillomavirus Infections
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
230
Fuzhou, Xiamen, Foshan, Guangzhou, Shenzhen, Zhongshan, Nanning, Dongguan
2026-07-01
Recruiting
Childhood-onset Lupus Nephritis Initial Glucocorticoid-dose Harmonization Trial (LIGHT Trial)
NCT07719140Childhood-onset Systemic Lupus Erythematosus, Lupus Nephritis (LN)
DrugPrednisone
Peking Union Medical College Hospital
Phase 4
198
Beijing, Chongqing, Shenzhen, Changsha, Nanjing, Changchun, Shanghai
2026-07
Recruiting
Mindfulness Intervention for Emotional Distress (MIED) in Patients With GERD
NCT07667894Gastroesophageal Reflux Disease, Emotional Distress
Xinghua Liu
Not applicable
500
Beijing, Baiyin, Shenzhen, Guiyang, Xingtai, Xinle, Chifeng, Hohhot
2026-06-29
Not yet open
A Phase โ…ข Clinical Study of SNA02-48 Injection
NCT07633119Tetanus
DrugsHTIG·Human tetanus immunoglobulin
Sinovac Life Sciences Co., Ltd.
Phase 3
600
Fuyang, Hefei, Beijing, Guangzhou, Shenzhen, Liuzhou, Zunyi, Shijiazhuang
2026-06-28
Recruiting
A Clinical Trial on the Efficacy and Safety of TQH3906 in the Treatment of Systemic Lupus Erythematosus
NCT07509892Systemic Lupus Erythematosus
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
198
Bengbu, Bozhou, Beijing, Chongqing, Lanzhou, Guangzhou, Jiangmen, Shenzhen
2026-06-22
By invitation
Predictive Efficacy of Fecal Calprotectin Assay by Magnetic Particle Chemiluminescence for Mucosal Healing in Moderate-to-Severe Ulcerative Colitis Patients Undergoing Initial Biologic Therapy๏ผˆPRECAL๏ผ‰
NCT07721441Ulcerative Colitis (UC)
Tang-Du Hospital
Observational
200
Beijing, Chongqing, Shenzhen, Wuhan, Nanjing, Shengyang, Qingdao, Xiโ€™an
2026-06-18
Recruiting
Chinese Phase II Trail of AS1501 in Acute-on-chronic Liver Failure (ACLF) Patients
NCT06916585Acute-On-Chronic Liver Failure
Shenzhen Third People's Hospital
Phase 2
96
Shenzhen
2026-06-15
Recruiting
Targeted Therapies for Immunological Non-Responders in People With HIV: A Multicenter Clinical Study
NCT07637877Immunological Non-Responders in People With HIV
Beijing 302 Hospital
Phase 2
21
Beijing, Guangzhou, Shenzhen
2026-06-15
Not yet open
A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Chronic Kidney Disease
NCT07647133Chronic Kidney Disease
Shenzhen Salubris Pharmaceuticals Co., Ltd.
Phase 2
249
Shenzhen, Nanjing
2026-06-15
Not yet open
The Clinical Trail to Evaluate the Efficacy and Safety of Anaprazole Sodium Enteric-coated Tablets Combined With Bismuth-containing Quadruple Therapy in Eradicating Helicobacter Pylori
NCT07606833HELICOBACTER PYLORI INFECTIONS
Xuanzhu Biopharmaceutical Co., Ltd.
Phase 3
556
Shenzhen
2026-06-10
Not yet open
Clinical Study on the Efficacy and Safety of CAR-DC in the Treatment of Advanced Solid Tumors
NCT07504445Advanced Solid Tumors
Peking University Shenzhen Hospital
Phase EARLY_PHASE1
10
Shenzhen
2026-06-10
Not yet open
Zanubrutinib Induction Followed by Delayed Fixed-Duration Combination With Sonrotoclax for CLL/SLL๏ผšStop Trial 2.0
NCT07682415CLL / SLL
DrugSonrotoclax
Yi Shuhua
Phase 2
60
Shenzhen, Zhengzhou, Changsha, Nanjing, Nanchang, Jinan, Tianjin
2026-06-08
Recruiting
A Study to Evaluate AHB-137 Injection in Treatment-naรฏve Participants With Chronic Hepatitis B
NCT07635186Chronic Hepatitis B
DrugAHB-137
Ausper Biopharma Co., Ltd.
Phase 2
320
Beijing, Chongqing, Xiamen, Guangzhou, Jiangmen, Meizhou, Qingyuan, Shenzhen
2026-06-05
Recruiting
A Cohort Study (Risk Prediction of HCC in Patients With Chronic Liver Disease)
NCT07820644Liver Cancer (Primary and Metastatic)
Cai Qingxian
Observational
15,000
Shenzhen
2026-06-01
Not yet open
Molecular Subtype-Guided Postoperative Radiotherapy for Phyllodes Tumor of the Breast: A Randomized Controlled Trial
NCT07657169Radiotherapy, Adjuvant, Phyllodes Breast Tumor, Prognosis, Molecular Typing
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
160
Guangzhou, Shenzhen, Jinan, Qingdao
2026-06-01
Not yet open
Dexmedetomidine-esketamine and tDCS for Prevention of Neurocognitive Complications After Surgery
NCT07576517Older Patients, Surgery, Dexmedetomidine, Esketamine
DrugDex-Esk
Peking University First Hospital
Phase 4
1,160
Beijing, Fuzhou, Shenzhen, Xi'an, Hangzhou
2026-06
Not yet open
Targeted Temperature Management on Delayed Neurocognitive Recovery in Older Patients After Major Cancer Surgery
NCT07655687Elderly Patients, Cancer Surgery, Hypothermia, Accidental, Targeted Temperature Management
Peking University First Hospital
Not applicable
1,512
Beijing, Shenzhen
2026-06
Recruiting
Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients
NCT07663253Multiple Myeloma
DrugsIsatuximab·Bortezomib·Lenalidomide·Dexamethasone
Shanghai Zhongshan Hospital
Observational
333
Beijing, Guangzhou, Shenzhen, Naning, Harbin, Zhengzhou, Wuhan, Nanjing
2026-06
Not yet open
Long-term Follow-up of Dexmedetomidine-esketamine and tDCS for Neurocognitive Complications After Surgery
NCT07576543Older Patients, Surgery, Dexmedetomidine, Esketamine
DrugDex-Esk
Peking University First Hospital
Phase 4
1,160
Beijing, Fuzhou, Shenzhen, Xi'an, Hangzhou
2026-06
Recruiting
A Dose REgimen-Finding Study of AGA2115 in Chinese Patients With Osteogenesis ImpeRfecta (EIR)
NCT07557446Osteogenesis Imperfecta (OI)
Angitia Biopharmaceuticals Guangzhou Limited
Phase 2
48
Beijing, Shenzhen, Suzhou, Shanghai
2026-06
Recruiting
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT07518186Multiple Myeloma
DrugsJNJ-79635322·Teclistamab
Janssen Research & Development, LLC
Phase 3
700
Beijing, Changchun, Chaoyang District, Chengdu, Guangzhou, Nanchang, Shenzhen, Tianjin
2026-05-31
Recruiting
Growth and Health Efficacy of Novel Infant Formula : A Randomized Trial
NCT07534735Infant Growth
Biostime (Changsha) Nutrition Foods Limited
Not applicable
120
Shenzhen
2026-05-27
Recruiting
Chinese Adults With Kidney Disease
NCT07522099Immunoglobulin A Nephropathy (IgAN), Complement 3 Glomerulopathy (C3G), IC-MPGN
DrugsSiRNA·Telitacicept
ADARx Pharmaceuticals, Inc.
Phase 2
30
Shenzhen, Guiyang, Zhengzhou, Baotou, Wuxi, Yantai, Beijing, Shandong
2026-05-21
Recruiting
A Clinical Trial Evaluating the Monkeypox Recombinant Protein Vaccine
NCT07495202Health Volunteer
Shanghai JunTop Biosciences Co., LTD
Phase 1
180
Shenzhen
2026-05-18
Recruiting
Diagnostic Value of the Liver Inflammation Index for MASH in Patients With T2DM and MAFLD
NCT07632677Type 2 Diabetes Mellitus (T2DM), MASH - Metabolic Dysfunction-Associated Steatohepatitis, Metabolic Dysfunction-associated Fatty Liver Disease
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Observational
10,000
Bengbu, Hefei, Wuhu, Guangzhou, Shenzhen, Nanning, Zunyi, Haikou
2026-05-15
Recruiting
AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
NCT07571109Obesity, Overweight, Obstructive Sleep Apnoea
DrugNNC0487-0111
Novo Nordisk A/S
Phase 3
300
Beijing, Guangzhou, Shenzhen, Luoyang, Nanjing, Tianjin
2026-05-05
Not yet open
Becotatug Vedotin Combined With Pucotenlimab as Neoadjuvant Therapy for Resectable Recurrent Head and Neck Squamous Cell Carcinoma After Progression on Immunotherapy: A Prospective Phase II Study
NCT07589049Head and Neck Squamous Cell Carcinoma
DrugsBecotatug Vedotin·Pucotenlimab
Sun Yat-sen University
Phase 2
42
Foshan, Guangzhou, Qingyuan, Shantou, Shenzhen, Zhanjiang, Ganzhou
2026-05
Rows per page Showing 1–100 of 576
1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/shenzhen

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 576 of those studies with a site in Shenzhen.

How many clinical trials are recruiting in Shenzhen?

337 of the 576 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 115 have not yet opened recruitment, 109 are active but closed to new participants, and 15 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Shenzhen), 576 studies
PhaseStudiesRecruitingShare
Phase 31266221.9%
Not applicable1076718.6%
Observational895815.5%
Phase 2896015.5%
Phase 1/2855214.8%
Phase 130145.2%
Phase 426124.5%
Phase 2/31592.6%
Phase EARLY_PHASE1931.6%

Most active sponsors

Lead sponsors with the most studies (Shenzhen)
Lead sponsorStudiesRecruiting
Shenzhen Geno-Immune Medical Institute430
Beijing Biotech3232
Sun Yat-sen University2316
Bristol-Myers Squibb198
Novartis Pharmaceuticals113
Shenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences1110
Shenzhen University General Hospital1110
Peking University First Hospital105
Peking University Shenzhen Hospital108
China National Center for Cardiovascular Diseases97
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.